medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2024, Number 5

<< Back Next >>

Rev Mex Urol 2024; 84 (5)

Epidemiology and clinical characteristics of bladder tumors recorded in a reference hospital in the Yucatan Peninsula

Monzón FJF, Ferreiro OFD, Mendoza AME, Flores TJP, Esqueda MA, Cruz NE

Language: Spanish
References: 15
Page: 1-10
PDF size: 256.29 Kb.


ABSTRACT

Introduction: in Mexico, bladder tumors rank fourth in urological tumor presentation, accounting for 14.4 % of cases, following prostate, testicular, and kidney cancer. The male-to-female ratio is 3.8:1. Bladder cancer is one of the main causes of consultation in patients with macroscopic hematuria and clot formation. Therefore, it should always be considered as an exclusion diagnosis in these patients due to its potential progression and impact on morbidity and mortality if detected in advanced stages.
Objectives: to determine the prevalence and clinical characteristics of registered cases of bladder cancer in the urology department.
Materials and methods: this is a descriptive, observational, cross-sectional study that will evaluate the medical records of patients with registered cases of bladder cancer in the Urology Department of the Hospital Regional de Alta Especialidad de la Península de Yucatán in Mexico, from from January 2017 to July 2021.
Results: of total 453 genitourinary tumors, 15.62 %, 29 patients with bladder tumor and a 4-year medical follow-up were included, bladder tumor is predominantly found in men with a male-to-female ratio of 3.83 men per woman. The mean age at diagnosis is 65 years. Among modifiable risk factors, smoking is the main factor affecting 44.8 % of the cases. According to the histological classification, the predominant subtype was urothelial carcinoma. The average time from symptom onset to medical attention by the patients was 11.9 months. T4 stage was detected in 27.59 % of the cases, with a mortality rate of 6.9 %.
Conclusion: bladder cancer is one of the three most common urological cancers, affecting the quality of life and with a high morbidity and mortality when detected at advanced stages, requiring aggressive surgical procedures with a high risk of complications.


REFERENCES

  1. de la Rosa-Cisneros AR, Viveros-Contreras C,Torres-Aguilar J, Hernández-León O, Arellano-Cuadros R, Martínez-Carrillo G. Experienciaen el tratamiento de cáncer vesical. RevistaMexicana de Urología. 2015;75(2): 58–63.https://doi.org/10.1016/j.uromx.2015.01.001

  2. Sedano-Basilio JE, Mayorga-Gómez E, Garza-Sainz G, Cornejo-Dávila V, Uberetagoyena-Tello de Meneses I, Palmeros-RodríguezAM, et al. Epidemiología de los tumoresgenitourinarios en una década. Revista Mexicanade Urología. 2016;76(3): 131–140. https://doi.org/10.1016/j.uromx.2016.01.004.

  3. Richters A, Aben KKH, Kiemeney LALM. Theglobal burden of urinary bladder cancer: anupdate. World Journal of Urology. 2020;38(8):1895–1904. https://doi.org/10.1007/s00345-019-02984-4.

  4. Bray F, Ferlay J, Soerjomataram I, Siegel RL,Torre LA, Jemal A. Global cancer statistics2018: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185countries. CA: a cancer journal for clinicians.2018;68(6): 394–424. https://doi.org/10.3322/caac.21492.

  5. Antoni S, Ferlay J, Soerjomataram I, ZnaorA, Jemal A, Bray F. Bladder Cancer Incidenceand Mortality: A Global Overview and RecentTrends. European Urology. 2017;71(1): 96–108.https://doi.org/10.1016/j.eururo.2016.06.010.

  6. Sanli O, Dobruch J, Knowles MA, Burger M,Alemozaffar M, Nielsen ME, et al. Bladdercancer. Nature Reviews. Disease Primers. 2017;3:17022. https://doi.org/10.1038/nrdp.2017.22.

  7. Lobo N, Afferi L, Moschini M, Mostafid H,Porten S, Psutka SP, et al. Epidemiology,Screening, and Prevention of Bladder Cancer.European Urology Oncology. 2022;5(6): 628–639.https://doi.org/10.1016/j.euo.2022.10.003.

  8. Lenfant L, Cancel-Tassin G, Gazut S, CompératE, Rouprêt M, Cussenot O. Genetic variabilityin 13q33 and 9q34 is linked to aggressivenesspatterns and a higher risk of progression of nonmuscle-invasive bladder cancer at the time ofdiagnosis. BJU international. 2021;127(3): 375–383. https://doi.org/10.1111/bju.15254.

  9. Saginala K, Barsouk A, Aluru JS, Rawla P,Padala SA, Barsouk A. Epidemiology of BladderCancer. Medical Sciences (Basel, Switzerland).2020;8(1): 15. https://doi.org/10.3390/medsci8010015.

  10. Lenis AT, Lec PM, Chamie K, Mshs MD. BladderCancer: A Review. JAMA. 2020;324(19):1980–1991. https://doi.org/10.1001/jama.2020.17598.

  11. Witjes JA, Bruins HM, Cathomas R, CompératEM, Cowan NC, Gakis G, et al. EuropeanAssociation of Urology Guidelines on Muscleinvasiveand Metastatic Bladder Cancer:Summary of the 2020 Guidelines. EuropeanUrology. 2021;79(1): 82–104. https://doi.org/10.1016/j.eururo.2020.03.055.

  12. Cumberbatch MGK, Jubber I, Black PC, EspertoF, Figueroa JD, Kamat AM, et al. Epidemiologyof Bladder Cancer: A Systematic Review andContemporary Update of Risk Factors in2018. European Urology. 2018;74(6): 784–795.https://doi.org/10.1016/j.eururo.2018.09.001.

  13. Hollenbeck BK, Dunn RL, Ye Z, HollingsworthJM, Skolarus TA, Kim SP, et al. Delays indiagnosis and bladder cancer mortality.Cancer. 2010;116(22): 5235–5242. https://doi.org/10.1002/cncr.25310

  14. Babjuk M, Burger M, Capoun O, Cohen D,Compérat EM, Dominguez Escrig JL, et al.European Association of Urology Guidelineson Non-muscle-invasive Bladder Cancer (Ta,T1, and Carcinoma in Situ). European Urology.2022;81(1): 75–94. https://doi.org/10.1016/j.eururo.2021.08.010.

  15. 15, Rozanec JJ, Secin FP. Epidemiología, etiología,prevención del cáncer vesical. ArchivosEspañoles de Urología 2020; 73 (10) 872–878




2020     |     www.medigraphic.com